CONTENTS

SECTION 1: INFECTION CONTROL

1. **Importance of Infection Control** ----2-6
   - Magnitude of the problem ---- 2
   - Pathogenesis ---- 2
   - Modes of spread ---- 3
   - Pathogens involved ---- 3
   - Mortality and morbidity ---- 3
   - Costs ---- 4
   - Isolation ---- 4
   - Prevention ---- 4
   - Infection control program ---- 5
2. **Hand Hygiene** ---- 7-22
   - Definitions ---- 8
   - Microorganism on skin ---- 8
   - Preparations used for hand hygiene ---- 8
   - Factors to consider when selecting hand hygiene products ---- 13
   - Methods used to promote improved hand hygiene ---- 14
   - Elements of health care worker educational and motivational programs should include ---- 14
   - Recommendation ---- 18
   - Performance indicators ---- 21
3. **Safe Injection Practice and Medical Waste Management** ---- 23-31
   - Importance of safe injection practice ---- 23
   - Unnecessary injections are unsafe ---- 24
   - Needlestick injury in the community ---- 24
   - Burden of disease associated with unsafe injection practices ---- 24
   - Safe and appropriate use of injections ---- 25
   - Unsafe practices ---- 26
   - Role of WHO towards safe injection practices ---- 26
   - Role of government of India ---- 26
   - Safe injection policies ---- 26
   - Safety measures ---- 27
   - Injection equipments ---- 27
   - Medical waste management ---- 28
   - Management of sharps waste ---- 29
   - Ways to improve injection safety in the institution ---- 30
4. **Infection Control in Hospital** ---- 32-39
   - Standard precautions ---- 32
   - Air control parameters for rooms of immunocompromised patients ---- 36
   - Additional precautions ---- 38
5. **Antibiotic Stewardship** ---- 41-48
   - Association between antimicrobial use and resistance ---- 41
   - Guidelines for developing all institutional program to enhance antimicrobial stewardship ---- 42

SECTION 2: LABORATORY DIAGNOSIS

6. **Complete Blood Count in Infections** ---- 51-57
   - Anemia ---- 52
   - Variation of leukocytes and differentials in infection ---- 53

Morphological changes associated with neutrophils in infection ----55
Platelet counts ----56
7. **Markers of Infection** ---- 59-68
Ideal characteristics of acute phase reactants----59
Acute phase response ----60
Modulators ----60
Classification ----61
Cytokines----61
C-reactive protein (CRP) ----61
Procalcitonin (PCT) ----63
Serum amyloid a (SAA) and serum amyloid p component (SAP) ----65
Adrenomedullin (AM)----66
Protein c (PRC)----66
Bottomline----66
8. **Laboratory Diagnosis of Infection** ---- 68-86
Collection of specimens ----68
Universal precautions and laboratory safety ----68
Direct microscopic examination ----69
Types of microscopy for the diagnosis of infections----69
Microscopy of unstained preparations ----69
Immunofluorescence ----71
Culture methods ----71
Typing microorganisms ----75
Polymerase chain reaction-based methods ----76
Methods of typing bacteria ----77
Culture of protozoa and helminthes ----77
Tissue culture for viruses and other intracellular organisms ----78
Serology in the detection of infection----78
Agglutination tests ----79
Complement fixation tests ----79
Indirect fluorescent antibody tests ----80
Enzyme-linked immunosorbent assay ----80
Molecular amplification methods ----82
Automation in culture and sensitivity ----84
9. **Radiology in Infectious Diseases** ----87-143
Neuroimaging ----89
Imaging of heart and vessels ----126
Imaging of abdomen----126
Imaging of liver ----128
Imaging of spleen ----131
Acute pancreatitis ----132
Urinary tract imaging ----133
Bone infection ----134

Section 3: Antibiotic Therapy

10. **Rational Antibiotic Therapy** ----144-150
Mechanism of action of antibiotics ----144
Antibiotics commonly used in children ----144
Mechanism of resistance to different antibiotics----147
Multiple antibiotic resistance ----148
Indications of antibiotic therapy ----148
Combination antibiotic therapy----149
11. **Strategies for Prevention of Antibiotic Resistance** ----151-158
Emergence of antimicrobial resistance ----151
Importance of infection control in hospital ----153

Surveillance for resistant bacterial pathogens ---- 154
Prevention of emergence of resistance ---- 154
Nonantimicrobial prevention strategies ---- 156
Community level prevention ---- 157
Controlling dissemination of resistant bacteria in hospitals ---- 157

Section 4: Rational use of Antimicrobials

12. **Third and Fourth Generation Cephalosporins** ---- 160-167
Classification ---- 160
Third generation cephalosporins ---- 161
Oral third general cephalosporins ---- 161
Parenteral third generation cephalosporins ---- 162
Third generation cephalosporins and beta-lactamase inhibitor combinations ---- 164
Combinations of third generation cephalosporins with probiotics ---- 164
Fourth generation cephalosporins ---- 165
Emerging cephalosporins ---- 166
13. **Beta-lactam/Beta-lactamase Inhibitor Combinations** ---- 168-177
Mechanism of action of β-lactam antibiotics ---- 168
Resistance to β-lactam antibiotics ---- 169
β-lactamases ---- 170
β-lactamase inhibitors ---- 170
β-lactam/β-lactamase inhibitor combinations in clinical use ---- 171
Further reading ---- 175
14. **Macrolides** ---- 178-189
Mechanism of action ---- 179
Drug resistance ---- 179
Pharmacokinetics ---- 180
Adverse events ---- 182
Drug interaction ---- 183
Therapeutic uses ---- 183
Disease specific use of macrolides in children ---- 185
Immunomodulatory effects of macrolide antibiotics in respiratory diseases ---- 187
15. **Aztreonam, Linezolid, Teicoplanin** ---- 190-199
Aztreonam ---- 190
Linezolid ---- 193
Teicoplanin ---- 195
16. **Carbapenems** ---- 200-209
Are all carbapenems the same? ---- 200
Mechanism of action ---- 201
Structure ---- 202
Spectrum ---- 202
Pharmacokinetics ---- 204
Clinical efficacy ---- 204
Indications and usage ---- 204
Adverse reactions ---- 207
Drug interactions ---- 207
Dosage and stability ---- 207
Contraindications ---- 208
17. **Vancomycin** ---- 210-218
Mechanism of action ---- 210
Spectrum of activity ---- 210
Mechanism of resistance ---- 211
Clinical implications of glycopeptides resistance ---- 212
Pharmacokinetics and pharmacodynamics ---- 213
Therapeutic uses ---- 214

Dosage and administration ---- 215
Duration of treatment ---- 217
Formulation ---- 217
Adverse effects ---- 217
18. **Antifungals** ---- 219-234
Established antifungal agents ---- 219
Newer antifungal agents ---- 226
19. **Antivirals** ---- 235-241
Antiviral agents for common viral infections ---- 235
20. **Antihelminthics** ---- 242-249
Why parasitic infections should be treated? ---- 242
Whom to treat? ---- 243
Classification of parasites ---- 243
Antihelminthic drugs ---- 244
Antihelminthic drug resistance: is it a threat or reality? ---- 245
Newer drugs ---- 246

Section 5: Management of Important Infections

21. **Pyogenic Meningitis** ---- 250-260
Background and etiology ---- 250
Diagnosis ---- 251
Supportive therapy and role of corticosteroids ---- 257
22. **Upper Respiratory Tract Infections** ---- 261-274
Sinusitis or rhinosinusitis ---- 261
Acute pharyngotonsillitis ---- 263
Acute otitis media ---- 268
Croup/acute epiglotitis ---- 271
23. **Community-acquired Pneumonia** ---- 275-283
Indications of chest X-ray ---- 275
X-ray as clue to the pathogens ---- 276
Follow-up chest X-ray ---- 276
General investigation ---- 276
Specific microbiological investigation ---- 277
Serologic diagnosis ---- 278
Lung aspiration ---- 278
Management of community-acquired pneumonia (CAP) ---- 278
Outpatient management of CAP ---- 280
Inpatient management of community-aquired pneumonia for severe disease ---- 281
Supportive therapy ---- 282
24. **Infective Endocarditis** ---- 284-294
Epidemiology ---- 284
Pathogenesis ---- 284
Clinical features ---- 286
Laboratory investigations ---- 287
Diagnosis ---- 288
Treatment ---- 289
25. **Acute Gastroenteritis** ---- 295-302
Etiology ---- *295*
Pathophysiology ---- 296
Clinical manifestation ---- 296
Laboratory investigations ---- 296
Management ---- 298
Antimicrobial in acute gastroenteritis ---- 300
Zinc in the treatment of acute diarrhea ---- 302
Probiotics ---- 302

26. **Enteric Fever** ---- 303-315
Epidemiology ---- 303
Source of infection ---- 304
Epidemiology of multidrug resistant typhoid fever (MDRTF) ---- 304
Clinical manifestations ---- 305
Diagnosis ---- 306
Treatment ---- 308
Antimicrobial therapy ---- 308
Complications of typhoid fever ---- 310
Treatment of severe typhoid fever ---- 312
Prognosis ---- 313
27. **Urinary Tract Infection** ---- 316-322
Diagnosis of UTI ---- 316
Management of acute UTI ---- 317
Investigations after UTI ---- 318
Role of prophylactic antibiotics ---- 320
High index of suspicion for further UTI ---- 321
28. **Neonatal Sepsis** ---- 323-348
Categorization based on onset ---- 323
Pathophysiology ---- 325
Incidence and prevalence ---- 327
Risk factors ---- 327
Clinical examination ---- 329
Certain common clinical patterns ---- 330
Differential diagnosis ---- 331
Investigations ---- 332
Medical treatment ---- 335
Supportive therapy ---- 338
Other innovations ---- 339
Surgical treatment ---- 339
Consultations ---- 340
Feeding of septic neonates ---- 340
Complications ---- 340
Prognosis ---- 340
Prevention of neonatal sepsis ---- 341
Prevention of late onset sepsis ---- 341
Annexure: antimicrobials in neonatal sepsis ---- 343
29. **Sepsis Beyond Neonatal Period** ---- 349-363
Various nomenclatures for disorders related to sepsis ---- 349
Causative organisms ---- 350
Pathophysiology ---- 350
Clinical features ---- 351
Investigations ---- 352
Antibiotic therapy ---- 355
Antifungal therapy ---- 357
Supportive management ---- 358
Prevention of BSI ---- 361
30. **Skin and Subcutaneous Tissue Infections** ---- 364-373
Impetigo ---- 365
Ecthyma ---- 366
Folliculitis, furuncles and carbuncles ---- 366
Cellulitis and erysipelas ---- 367
Necrotizing skin and soft tissue infection ---- 368
Necrotizing fascistis ---- 368
Paronychia ---- 370
Intertrigo ---- 370

Blistering dactilitis ---- 371
Perianal infectious dermatitis/perianal streptococcal dermatitis ---- 371
Erythrasma ---- 371
Human bite ---- 372
Animal bite ---- 372
31. **Bone and Joint Infections** ---- 374-388
Osteomyelitis ---- 374
Pyogenic arthritis ---- 383
32. **Tuberculosis** ---- 389-409
Etiologic agent ---- 389
Antigenic properties ---- 390
Pathophysiology ---- 390
Infection, resistance and immunity ---- 391
Portal of entry ---- 392
Incubation period ---- 392
Pathogenesis ---- 392
Variations in the reaction to tubercle bacilli ---- 394
Fate of tuberculous lesion ---- 395
Spread of tuberculosis in the body ---- 395
Presentations of tuberculosis in children ---- 396
Pathogenesis of tuberculosis in various organs ---- 396
Manifestation of tuberculosis according to various sites ---- 396
Diagnosis ---- 401
33. **HIV Disease** ---- 410-423
Epidemiology ---- 410
Transmission ---- 411
Vertical transmission of HIV ---- 411
Breast milk acquired HIV-I infection ---- 411
Adolescent and HIV ---- 412
Etiopathogenesis ---- 412
Clinical features ---- 412
Revised who clinical staging of HIV/AIDS ---- 413
Opportunistic infections (OI) ---- 414
Diagnosis of HIV infection ---- 415
Management ---- 415
Clinical and immunological classification ---- 416
Specific therapy—antiretroviral drug therapy (ART) ---- 417
Reduction of vertical transmission ---- 420
Other aspects of management ---- 420
Counseling ---- 421

SECTION 6: SERIOUS INFECTIONS

34. **Nosocomial Infections** ---- 424-439
Rates of NI ---- 424
Sites of NI ---- 425
Etiology and antimicrobial resistance pattern of nosocomial infections in india ---- 425
General principles in diagnosing nosocomial infections ---- 425
General principles in treating nosocomial infections ---- 426
Bloodstream and catheter related infections ---- 430
Health care associated pneumonia ---- 433
Urinary tract infections ---- 435
Surgical site infections ---- 436
NI in neonates ---- 437
NI in immunocompromised ---- 437

35. **Ventilator Associated Pneumonia** ---- 440-450
Pathophysiology ---- 440
Incidence ---- 440
Etiology ---- 441
Definition ---- 441
Differential diagnosis ---- 442
Invasive diagnostic tests ---- 442
Prevention ---- 443
Treatment of VAP ---- 447
36. **Infections In Immunocompromised Children** ---- 451-463
Barriers against infection ---- 451
Infections associated with common congenital immune deficiencies ---- 452
Infections associated with secondary immunodeficiencies ---- 456
Diagnosis of infections in immunocompromised children ---- 458
Treatment ---- 459
37. **Infection Associated Hemophagocytic Lymphohistiocytosis** ---- 464-470
Types of hemophagocytic lymphohistiocytosis (HLH) ---- 464
Underlying causes of reactive HLH ---- 465
Malignancy ---- 465
Infection associated HLH ---- 465
Further reading ---- 469

Section 7: Life-threatening Tropical Infections

38. **Arthropod Borne Infections—Severe Malaria, Dengue, Japanese Encephalitis** 471-493
Severe Malaria ---- 471
Clinical features ---- 471
Laboratory features ---- 471
Diagnosis of malaria ---- 472
Management of severe malaria in children ---- 474
Supportive management ---- 475
Management of complications of malaria ---- 477
Dengue ---- 479
Pathophysiology ---- 479
Classification of dengue ---- 479
Clinical manifestation ---- 481
Laboratory diagnosis ---- 483
Management ---- 485
Management in High Dependency Unit (HDU) ---- 486
Japanese Encephalitis ---- 487
Epidemiology ---- 487
Pathogenesis ---- 488
Clinical manifestation ---- 488
Differential diagnosis ---- 489
Diagnosis ---- 489
Management ---- 489
39. **Vaccine Preventable Infections—Diphtheria, Tetanus, Poliomyelitis** ---- 494-511
Diphtheria ---- 494
Etiology ---- 494
Epidemiology ---- 494
Clinical manifestations ---- 495
Complications ---- 496
Diagnosis ---- 496
Differential diagnosis ---- 497
Treatment ---- 497

Prognosis---497
Prevention---498
Tetanus---498
Epidemiology---498
Etiology---499
Clinical manifestations---499
Diagnosis---499
Treatment---500
Differential diagnosis---500
Prognosis---500
Prevention---501
Wound management---501
Poliomyelitis---501
Epidemiology---501
Pathogenesis---502
Clinical manifestations---502
Differential diagnosis---505
Diagnosis of poliomyelitis---506
Management---506
Indications for hospitalization---508
Prognosis---508
Disease control strategies---508
Surveillance---509
Vaccines against poliomyelitis---509
Index---